NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Intellia downgraded to market perform at Morgan Stanley on concerns for ATTR-CM candidate nexiguran ziclumeran. Read more ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

Financial writer recommends buying Intellia Therapeutics, Inc. stock as it restructures, focusing on late-stage programs for ...

Longer Term Trading Plans for NTLA. Buy NTLA near 10.06 target 13.33 stop loss @ 10.03 Details; The technical summary data ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

Intellia Therapeutics Inc (NTLA) stock saw a modest uptick, ending the day at $9.5 which represents a slight increase of $0.08 or 0.85% from the prior close of $9.42. The stock opened at $9.48 and ...

Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a report published on Friday morning,RTT News reports. They currently have a $10.00 price ...